Rhinolast 140 micrograms per Spray, Nasal Spray
*Company:
Mylan IRE Healthcare LtdStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 24 February 2022
File name
ie-pl-rhinolast-excipient name-clean.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 24 February 2022
File name
ie-spc-rhinolast-excipient name-clean.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 6.1 - List of excipients
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 27 April 2021
File name
ie-pl-rhinolast-clean (delete MMC).pdf
Reasons for updating
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 16 October 2018
File name
ie-pl-rhinolast-clean-mahtransfer.pdf
Reasons for updating
- New PIL for new product
Updated on 16 October 2018
File name
ie-spc-rhinolast-clean-mahtransfer.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 09 March 2015
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 09 March 2015
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
In section 4.6: Subheading has been expanded to include fertility
In section 4.8: the ADR statement was added
In section 10: the date of revision has changed
Updated on 09 March 2015
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 4.6: Subheading has been expanded to include fertility
In section 4.8: the ADR statement was added
In section 10: the date of revision has changed
Updated on 07 June 2012
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
In section 9; the renewal date has been revised
In section 10; the revision date is now May 2012
Updated on 07 June 2012
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 9; the renewal date has been revised
In section 10; the revision date is now May 2012
Updated on 08 April 2011
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 08 April 2011
Reasons for updating
- New SPC for medicines.ie